A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer.

Gene Expression Omnibus The Cancer Genome Atlas ceRNA network immune-related lncRNAs ovarian cancer prognostic signature

Journal

Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621

Informations de publication

Date de publication:
2021
Historique:
received: 19 04 2021
accepted: 29 06 2021
entrez: 9 8 2021
pubmed: 10 8 2021
medline: 10 8 2021
Statut: epublish

Résumé

Ovarian cancer (OC), the most lethal gynecologic malignancy, ranks fifth in cancer deaths among women, largely because of late diagnosis. Recent studies suggest that the expression levels of immune-related long non-coding RNAs (lncRNAs) play a significant role in the prognosis of OC; however, the potential of immune-related lncRNAs as prognostic factors in OC remains unexplored. In this study, we aimed to identify a potential immune-related lncRNA prognostic signature for OC patients. We used RNA sequencing and clinical data from The Cancer Genome Atlas and the Gene Expression Omnibus database to identify immune-related lncRNAs that could serve as useful biomarkers for OC diagnosis and prognosis. Univariate Cox regression analysis was used to identify the immune-related lncRNAs with prognostic value. Functional annotation of the data was performed through the GenCLiP310 website. Seven differentially expressed lncRNAs (AC007406.4, AC008750.1, AL022341.2, AL133351.1, FAM74A7, LINC02229, and HOXB-AS2) were found to be independent prognostic factors for OC patients. The Kaplan-Meier curve indicated that patients in the high-risk group had a poorer survival outcome than those in the low-risk group. The receiver operating characteristic curve revealed that the predictive potential of the immune-related lncRNA signature for OC was robust. The prognostic signature of the seven lncRNAs was successfully validated in the GSE9891, GSE26193 datasets and our clinical specimens. Multivariate analyses suggested that the signature of the seven lncRNAs was an independent prognostic factor for OC patients. Finally, we constructed a nomogram model and a competing endogenous RNA network related to the lncRNA prognostic signature. In conclusion, our study reveals novel immune-related lncRNAs that may serve as independent prognostic factors in OC.

Identifiants

pubmed: 34367253
doi: 10.3389/fgene.2021.694009
pmc: PMC8335165
doi:

Types de publication

Journal Article

Langues

eng

Pagination

694009

Informations de copyright

Copyright © 2021 Pan and Bi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52
pubmed: 25378301
iScience. 2019 Jul 26;17:242-255
pubmed: 31307004
Sci Rep. 2020 Oct 9;10(1):16945
pubmed: 33037279
Cell Death Discov. 2021 Mar 26;7(1):61
pubmed: 33771981
Mol Cancer. 2017 Jan 19;16(1):16
pubmed: 28103885
Oncotarget. 2016 May 31;7(22):32433-48
pubmed: 27074572
Cell Immunol. 2021 May;363:104321
pubmed: 33773377
BMC Cancer. 2019 Aug 16;19(1):813
pubmed: 31419958
Biochim Biophys Acta Mol Basis Dis. 2020 Jul 1;1866(7):165757
pubmed: 32147422
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32041817
J Int Med Res. 2020 Nov;48(11):300060520970761
pubmed: 33179541
Front Genet. 2021 Feb 16;11:566497
pubmed: 33664764
Sci Rep. 2021 Feb 18;11(1):4219
pubmed: 33603134
Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7
pubmed: 29232467
Mol Ther Nucleic Acids. 2019 Sep 6;17:92-101
pubmed: 31234009
Med Sci Monit. 2020 Jun 12;26:e922854
pubmed: 32529991
Sci Rep. 2017 Apr 7;7(1):752
pubmed: 28389671
Genomics. 2021 May;113(3):1504-1513
pubmed: 33771634
Brief Bioinform. 2021 May 20;22(3):
pubmed: 32382761
Front Genet. 2021 Mar 05;12:638960
pubmed: 33747049
Exp Ther Med. 2019 Apr;17(4):3035-3040
pubmed: 30906477
Biomed Pharmacother. 2019 Mar;111:395-401
pubmed: 30594777
J Clin Oncol. 2019 Sep 20;37(27):2460-2471
pubmed: 31403857
Brief Bioinform. 2021 May 20;22(3):
pubmed: 32436954
Cancer Res. 2021 Jun 15;81(12):3187-3199
pubmed: 33771898
Mol Neurobiol. 2018 May;55(5):3684-3697
pubmed: 28527107
Front Genet. 2020 Sep 04;11:1037
pubmed: 33101369
Trends Biochem Sci. 2016 Sep;41(9):761-772
pubmed: 27499234
Onco Targets Ther. 2020 Mar 26;13:2527-2535
pubmed: 32273723
Front Oncol. 2021 Jan 21;10:605877
pubmed: 33552977
Front Oncol. 2020 Oct 14;10:560779
pubmed: 33163400
Ann Transl Med. 2019 Nov;7(22):641
pubmed: 31930042
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
EBioMedicine. 2019 Oct;48:414-424
pubmed: 31594752
Onco Targets Ther. 2020 Mar 17;13:2319-2331
pubmed: 32256083
Int Immunopharmacol. 2021 Jun;95:107559
pubmed: 33756228

Auteurs

Xue Pan (X)

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.

Fangfang Bi (F)

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.

Classifications MeSH